All news

FHTX stock falls 31% as trial halt triggers 40% staff cut

Alpha Vantage · Pluang · · AI-summarised by FinFlash

Pomerantz LLP is investigating Foghorn Therapeutics for potential securities fraud after the company announced it would not advance its FHD-909 trial or collaboration with Lilly and would cut its workforce by 40%. This news led to a 30.82% drop in Foghorn's stock price to $2.02 on October 2, 2026. The investigation aims to protect investors who suffered losses due to these developments.

Read original source

FHTX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.